243 related articles for article (PubMed ID: 24833041)
1. Near-infrared fluorescence imaging of non-Hodgkin's lymphoma CD20 expression using Cy7-conjugated obinutuzumab.
Lin X; Zhu H; Luo Z; Hong Y; Zhang H; Liu X; Ding H; Tian H; Yang Z
Mol Imaging Biol; 2014 Dec; 16(6):877-87. PubMed ID: 24833041
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive Evaluation of CD20 Expression Using
Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
Camacho X; Machado CL; García MF; Gambini JP; Banchero A; Fernández M; Oddone N; Bertolini Zanatta D; Rosal C; Buchpiguel CA; Chammas R; Riva E; Cabral P
Oncology; 2017; 92(4):229-242. PubMed ID: 28196364
[TBL] [Abstract][Full Text] [Related]
6. CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphoma.
Kim JR; Lee D; Kim Y; Kim JY
Cancer Immunol Immunother; 2023 Jun; 72(6):1567-1580. PubMed ID: 36534148
[TBL] [Abstract][Full Text] [Related]
7. A novel near-infrared fluorescence imaging probe for in vivo neutrophil tracking.
Xiao L; Zhang Y; Berr SS; Chordia MD; Pramoonjago P; Pu L; Pan D
Mol Imaging; 2012; 11(5):372-82. PubMed ID: 22954181
[TBL] [Abstract][Full Text] [Related]
8. Dual functional molecular imaging probe targeting CD20 with PET and optical imaging.
Paudyal P; Paudyal B; Iida Y; Oriuchi N; Hanaoka H; Tominaga H; Ishikita T; Yoshioka H; Higuchi T; Endo K
Oncol Rep; 2009 Jul; 22(1):115-9. PubMed ID: 19513512
[TBL] [Abstract][Full Text] [Related]
9. ImmunoPET of Malignant and Normal B Cells with
Zettlitz KA; Tavaré R; Knowles SM; Steward KK; Timmerman JM; Wu AM
Clin Cancer Res; 2017 Dec; 23(23):7242-7252. PubMed ID: 28928164
[No Abstract] [Full Text] [Related]
10. Obinutuzumab for B-cell malignancies.
Owen CJ; Stewart DA
Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
[TBL] [Abstract][Full Text] [Related]
11. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of fibrin deposition in deep vein thrombosis using fibrin-targeted near-infrared fluorescence.
Hara T; Bhayana B; Thompson B; Kessinger CW; Khatri A; McCarthy JR; Weissleder R; Lin CP; Tearney GJ; Jaffer FA
JACC Cardiovasc Imaging; 2012 Jun; 5(6):607-15. PubMed ID: 22698530
[TBL] [Abstract][Full Text] [Related]
13. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.
Wang K; Wang K; Li W; Huang T; Li R; Wang D; Shen B; Chen X
Acta Radiol; 2009 Dec; 50(10):1095-103. PubMed ID: 19922304
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice.
Zou P; Xu S; Povoski SP; Wang A; Johnson MA; Martin EW; Subramaniam V; Xu R; Sun D
Mol Pharm; 2009; 6(2):428-40. PubMed ID: 19718796
[TBL] [Abstract][Full Text] [Related]
15. Near-infrared dye-labeled antibody COC183B2 enables detection of tiny metastatic ovarian cancer and optimizes fluorescence-guided surgery.
Chen J; Guo Y; Li H; Zhang C; Chang X; Ma R; Cheng H; Ye X; Cui H; Li Y
J Surg Oncol; 2020 Nov; 122(6):1207-1217. PubMed ID: 32705686
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab for the treatment of indolent lymphoma.
Edelmann J; Gribben JG
Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
[TBL] [Abstract][Full Text] [Related]
17. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
18. Ultrasensitive near-infrared fluorescence-enhanced probe for in vivo nitroreductase imaging.
Li Y; Sun Y; Li J; Su Q; Yuan W; Dai Y; Han C; Wang Q; Feng W; Li F
J Am Chem Soc; 2015 May; 137(19):6407-16. PubMed ID: 25923361
[TBL] [Abstract][Full Text] [Related]
19. Cerenkov-Activated Sticky Tag for In Vivo Fluorescence Imaging.
Das S; Haedicke K; Grimm J
J Nucl Med; 2018 Jan; 59(1):58-65. PubMed ID: 28912146
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
